GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases

Prior tumor cell studies have shown that the drugs sorafenib (Nexavar) and regorafenib (Stivarga) reduce expression of the chaperone GRP78. Sorafenib/regorafenib and the multi‐kinase inhibitor pazopanib (Votrient) interacted with sildenafil (Viagra) to further rapidly reduce GRP78 levels in eukaryot...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Jane L., Tavallai, Mehrad, Nourbakhsh, Aida, Fidanza, Abigail, Cruz‐Luna, Tanya, Smith, Elizabeth, Siembida, Paul, Plamondon, Pascale, Cycon, Kelly A., Doern, Christopher D., Booth, Laurence, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843173/
https://www.ncbi.nlm.nih.gov/pubmed/25858032
http://dx.doi.org/10.1002/jcp.25014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843173/
https://www.ncbi.nlm.nih.gov/pubmed/25858032
http://dx.doi.org/10.1002/jcp.25014

Ejemplares similares